CELA2A and inflammatory bowel disease: Precisely because ELA2A appears as a trigger of both barrier and immune balance defects, specific inhibition of this protease, using ELA2A selective inhibitors, could be considered as an interesting therapeutic approach to restore mucosal homoeostasis in IBD.